Department of Chemistry, Wayne State University , Detroit, Michigan 48202, United States.
Institute of Medical Microbiology, University of Zurich , 8006 Zurich, Switzerland.
J Am Chem Soc. 2017 Oct 18;139(41):14611-14619. doi: 10.1021/jacs.7b07754. Epub 2017 Oct 9.
The preparation of a series of four analogues of the aminoglycoside antibiotics neomycin and paromomycin is described in which ring I, involved in critical binding interactions with the ribosomal target, is replaced by an apramycin-like dioxabicyclo[4.4.0]octane system. The effect of this modification is to lock the hydroxymethyl side chain of the neomycin or paromomycin ring I, as part of the dioxabicyclooctane ring, into either the gauche-gauche or the gauche-trans conformation (respectively, axial or equatorial to the bicyclic system). The antiribosomal activity of these compounds is investigated with cell-free translation assays using both bacterial ribosomes and recombinant hybrid ribosomes carrying eukaryotic decoding A site cassettes. Compounds substituted with an equatorial hydroxyl or amino group in the newly formed ring are considerably more active than their axial diastereomers, lending strong support to crystallographically derived models of aminoglycoside-ribosome interactions. One such bicyclic compound carrying an equatorial hydroxyl group has activity equal to that of the parent yet displays better ribosomal selectivity, predictive of an enhanced therapeutic index. A paromomycin analog lacking the hydroxymethyl ring I side chain is considerably less active than the parent. Antibacterial activity against model Gram negative and Gram positive bacteria is reported for selected compounds, as is activity against ESKAPE pathogens and recombinant bacteria carrying specific resistance determinants. Analogues with a bicyclic ring I carrying equatorial amino or hydroxyl groups mimicking the bound side chains of neomycin and paromomycin, respectively, show excellent activity and, by virtue of their novel structure, retain this activity in strains that are insensitive to the parent compounds.
本文描述了一系列氨基糖苷类抗生素新霉素和巴龙霉素类似物的制备,其中涉及与核糖体靶标关键结合相互作用的环 I 被类似 Apramycin 的二氧杂环[4.4.0]辛烷系统取代。这种修饰的效果是将新霉素或巴龙霉素环 I 的羟甲基侧链作为二氧杂环辛烷环的一部分,锁定为 gauche-gauche 或 gauche-trans 构象(分别为轴向或赤道向双环系统)。使用含有真核解码 A 位盒的细菌核糖体和重组杂种核糖体的无细胞翻译测定法研究了这些化合物的抗核糖体活性。在新形成的环中具有赤道羟基或氨基取代的化合物比其轴向非对映异构体的活性高得多,这强烈支持了基于晶体学的氨基糖苷-核糖体相互作用模型。一种具有赤道羟基的双环化合物具有与母体相等的活性,但显示出更好的核糖体选择性,预示着治疗指数的提高。缺乏羟甲基环 I 侧链的巴龙霉素类似物的活性比母体低得多。报道了选定化合物对模型革兰氏阴性和革兰氏阳性菌的抗菌活性,以及对 ESKAPE 病原体和携带特定耐药决定因素的重组菌的活性。具有双环环 I 携带赤道氨基或羟基的类似物分别模拟新霉素和巴龙霉素的结合侧链,表现出极好的活性,并且由于其新颖的结构,在对母体化合物不敏感的菌株中保留了这种活性。